Asia Pacific Rapid Diagnostics will grow by 10.9% annually with a total addressable market cap of $ 129,373.7 million over 2022-2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations.
Highlighted with 35 tables and 64 figures, this 126-page report "Asia Pacific Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire Asia Pacific Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Consumables
• Analyzers/Instruments
Based on Prescription, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Professional Diagnostics
• OTC Based Testing
By Platform, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Immunoassays
o Lateral Flow Assays
o Serological Assays
o Other Immunoassays
• Molecular Detection
o Polymerase Chain Reaction (PCR)
o Other Molecular Detection Tests
• Other Platforms
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
o COVID-19 Testing
o Healthcare-associated Infections (HAI) Testing
o Hepatitis Testing
o Tropical Diseases Testing
o HIV Testing
o Influenza Testing
o Sexually Transmitted Diseases (STD) Testing
o Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals & Clinics
• Laboratories
• Individuals/Homecare
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Prescription and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Diagnostics
ACON Laboratories
Becton Dickinson and Co.
BioMérieux S.A.
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems
Danaher Corp.
F. Hoffmann La Roche Ltd.
GlySens Inc.
Meridian Bioscience Inc.
OraSure Technologies Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trinity Biotech Plc
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter's Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product 43
3.1 Market Overview by Product 43
3.2 Consumables 45
3.3 Analyzers/Instruments 46
4 Segmentation of Asia Pacific Market by Prescription 47
4.1 Market Overview by Prescription 47
4.2 Professional Diagnostics 49
4.3 OTC Based Testing 50
5 Segmentation of Asia Pacific Market by Platform 51
5.1 Market Overview by Platform 51
5.2 Immunoassays 53
5.2.1 Lateral Flow Assays 55
5.2.2 Serological Assays 56
5.2.3 Other Immunoassays 57
5.3 Molecular Detection 58
5.3.1 Polymerase Chain Reaction (PCR) 59
5.3.2 Other Molecular Detection Tests 60
5.4 Other Platforms 61
6 Segmentation of Asia Pacific Market by Application 62
6.1 Market Overview by Application 62
6.2 Blood Glucose Testing 64
6.3 Cardiometabolic Testing 65
6.4 Infectious Disease Testing 66
6.4.1 COVID-19 Testing 68
6.4.2 Healthcare-associated Infections (HAI) Testing 69
6.4.3 Hepatitis Testing 70
6.4.4 Tropical Diseases Testing 71
6.4.5 HIV Testing 72
6.4.6 Influenza Testing 73
6.4.7 Sexually Transmitted Diseases (STD) Testing 74
6.4.8 Other Infectious Diseases Testing 75
6.5 Blood Coagulation Testing 76
6.6 Hematology Testing 77
6.7 Cancer Testing 78
6.8 Drug Abuse Testing 79
6.9 Pregnancy & Fertility Testing 80
6.10 Other Applications 81
7 Segmentation of Asia Pacific Market by End User 82
7.1 Market Overview by End User 82
7.2 Hospitals & Clinics 84
7.3 Laboratories 85
7.4 Individuals/Homecare 86
7.5 Other End Users 87
8 Asia-Pacific Market 2021-2031 by Country 88
8.1 Overview of Asia-Pacific Market 88
8.2 Japan 91
8.3 China 94
8.4 Australia 96
8.5 India 98
8.6 South Korea 100
8.7 Rest of APAC Region 102
9 Competitive Landscape 104
9.1 Overview of Key Vendors 104
9.2 New Product Launch, Partnership, Investment, and M&A 109
9.3 Company Profiles 111
Abbott Diagnostics 111
ACON Laboratories 113
Becton Dickinson and Co. 114
BioMérieux S.A. 115
Bio-Rad Laboratories, Inc. 116
Chembio Diagnostic Systems 117
Danaher Corp. 118
F. Hoffmann La Roche Ltd. 119
GlySens Inc. 120
Meridian Bioscience Inc. 121
OraSure Technologies Inc. 122
Siemens Healthineers AG 123
Thermo Fisher Scientific Inc. 124
Trinity Biotech Plc 125
RELATED REPORTS 126
Executive Summary
Azoth Analytics has released a research report titled "Global Infectious Disease In vitro Diagnostics Market (2024 Edition)" which provides a complete analysis of the Global Infectious Disease In vitro Diagnostics industry in terms of market segmentation By Technology ...
The In Vitro Diagnostics (IVD) Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufact...
The Rapid Cell Cryopreservation Solution Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape...
The global market for veterinary rapid test kits is positioned for significant revenue growth in the coming years. A number of factors are driving this growth, including a rise in companion animal ownership and an increasing focus on livestock health and disease prevention. These dynamics, among oth...
Asia Pacific cutting tools market will grow by 6.0% annually with a total addressable market cap of $163.03 billion over 2024-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for powe...
Asia Pacific paper machine clothing (PMC) market will grow by 5.3% annually with a total addressable market cap of $7.27 billion over 2024-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking p...
Asia Pacific endoscopy devices market will grow by 7.7% annually with a total addressable market cap of $150.27 billion over 2024-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic c...
Asia Pacific digital health and wellness market will grow by 20.8% annually with a total addressable market cap of $3,072.0 billion over 2024-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphon...
Asia Pacific connected healthcare device market will grow by 21.1% annually with a total addressable market cap of $495.3 billion over 2024-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetrat...
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...